Nateglinide Disease Interactions
There are 4 disease interactions with nateglinide.
Meglitinides (applies to nateglinide) type I diabetes
Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Type 1, Diabetic Ketoacidosis
The use of meglitinides is contraindicated in patients with type I diabetes or for the treatment of diabetic ketoacidosis, with or without coma.
References
- (2001) "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals
Oral hypoglycemic agents (applies to nateglinide) cardiovascular risk
Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease
The use of oral hypoglycemic agents may be associated with an increased risk of cardiovascular mortality compared to treatment with diet alone or diet with insulin. This warning is based on the University Group Diabetes Program (UGDP) study, a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. Patients treated with diet plus a fixed dosage of either tolbutamide (a sulfonylurea) or phenformin (a biguanide) for 5 to 8 years had a cardiovascular mortality rate approximately 2.5 times that of patients treated with diet alone, resulting in discontinuation of both these treatments in the study. Despite controversy regarding interpretation of these results, clinicians and patients should be aware of the potential risk when making treatment decisions for diabetes, particularly in the presence of underlying cardiovascular disease. Data are not available for other sulfonylureas or biguanides, nor for hypoglycemic agents belonging to other classes. However, given the similarities in chemical structure and/or mode of action, the same caution should be applied.
References
- (2002) "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals
- (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals
- "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- (2001) "Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel
- (2001) "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn
- (2001) "Product Information. Orinase (tolbutamide)." Pharmacia and Upjohn
- (2001) "Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company
Insulin/oral hypoglycemic agents (applies to nateglinide) hypoglycemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems
Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.
References
- (2002) "Product Information. Diabinese (chlorpropamide)." Pfizer U.S. Pharmaceuticals
- (2002) "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals
- "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
- (2002) "Product Information. Micronase (glyburide)." Pharmacia and Upjohn
- "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
- (2001) "Product Information. Amaryl (glimepiride)." Hoechst Marion Roussel
- (2001) "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Tolinase (tolazamide)." Pharmacia and Upjohn
- (2001) "Product Information. Dymelor (acetohexamide)." Lilly, Eli and Company
- (2001) "Product Information. Lantus (insulin glargine)." Aventis Pharmaceuticals
- (2022) "Product Information. NovoLOG (insulin aspart)." Novo Nordisk Pharmaceuticals Inc
- (2001) "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals
- (2004) "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals
- (2005) "Product Information. Levemir (insulin detemir)." Novo Nordisk Pharmaceuticals Inc
- (2015) "Product Information. Tresiba FlexTouch (insulin degludec)." Novo Nordisk Pharmaceuticals Inc
- (2018) "Product Information. Glucophage (metFORMIN)." EMD Serono Inc, SUPPL-34
Nateglinide (applies to nateglinide) liver disease
Moderate Potential Hazard, Moderate plausibility.
Nateglinide is primarily metabolized in the liver to both pharmacologically active and inactive substances. Patients with impaired liver function may be exposed to higher concentrations of nateglinide and its associated metabolites. Higher serum drug levels, in addition to diminished gluconeogenic capacity secondary to hepatic insufficiency, may increase the potential for severe hypoglycemic episodes. Therapy with nateglinide should be administered cautiously in patients with liver disease. Dosage adjustments may be necessary in moderate to severe hepatic impairment, although clinical data are lacking.
References
- (2001) "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals
Nateglinide drug interactions
There are 440 drug interactions with nateglinide.
Nateglinide alcohol/food interactions
There is 1 alcohol/food interaction with nateglinide.
More about nateglinide
- nateglinide consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: meglitinides
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.